CN114286811B - 富马酸单甲酯的前药 - Google Patents
富马酸单甲酯的前药 Download PDFInfo
- Publication number
- CN114286811B CN114286811B CN202080041560.5A CN202080041560A CN114286811B CN 114286811 B CN114286811 B CN 114286811B CN 202080041560 A CN202080041560 A CN 202080041560A CN 114286811 B CN114286811 B CN 114286811B
- Authority
- CN
- China
- Prior art keywords
- compound
- fumarate
- counterion
- iodine
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 title claims abstract description 29
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229940005650 monomethyl fumarate Drugs 0.000 title claims abstract description 28
- 239000000651 prodrug Substances 0.000 title abstract description 9
- 229940002612 prodrug Drugs 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 61
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical group OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical group OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 239000011630 iodine Substances 0.000 claims 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical group OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 4
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical group OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- 229910002651 NO3 Inorganic materials 0.000 claims 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical group OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims 4
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical group [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims 4
- 239000001177 diphosphate Substances 0.000 claims 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 4
- 235000011180 diphosphates Nutrition 0.000 claims 4
- 229940050410 gluconate Drugs 0.000 claims 4
- 229940001447 lactate Drugs 0.000 claims 4
- 229940099584 lactobionate Drugs 0.000 claims 4
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical group OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims 4
- 229940049920 malate Drugs 0.000 claims 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical group OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical group [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 4
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical group COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 4
- 229940095064 tartrate Drugs 0.000 claims 4
- 229940070710 valerate Drugs 0.000 claims 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims 1
- -1 bitartrates Chemical class 0.000 description 28
- 239000007787 solid Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical compound ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 4
- VXWDQYHMYFTTBQ-UHFFFAOYSA-N chloromethyl pyridine-3-carboxylate Chemical compound ClCOC(=O)C1=CC=CN=C1 VXWDQYHMYFTTBQ-UHFFFAOYSA-N 0.000 description 4
- 229960004419 dimethyl fumarate Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- BJDYCCHRZIFCGN-UHFFFAOYSA-N pyridin-1-ium;iodide Chemical compound I.C1=CC=NC=C1 BJDYCCHRZIFCGN-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- XDEPGMKZSGPMRZ-FXRZFVDSSA-N [I-].C(N)(=O)C=1C=[N+](C=CC=1)COC(\C=C\C(=O)OC)=O Chemical compound [I-].C(N)(=O)C=1C=[N+](C=CC=1)COC(\C=C\C(=O)OC)=O XDEPGMKZSGPMRZ-FXRZFVDSSA-N 0.000 description 2
- GIRSODZKTDSRNW-IPZCTEOASA-N [I-].COC(/C=C/C(=O)OC[N+]1=CC(=CC=C1)C(NC)=O)=O Chemical compound [I-].COC(/C=C/C(=O)OC[N+]1=CC(=CC=C1)C(NC)=O)=O GIRSODZKTDSRNW-IPZCTEOASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 2
- ISKTYGSJCPZVJU-NSCUHMNNSA-N 4-o-(chloromethyl) 1-o-methyl (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCl ISKTYGSJCPZVJU-NSCUHMNNSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- JDDOJSNHPGULAY-IPZCTEOASA-M [I-].COC(/C=C/C(=O)OCOC(=O)C=1C=[N+](C=CC=1)C)=O Chemical compound [I-].COC(/C=C/C(=O)OCOC(=O)C=1C=[N+](C=CC=1)C)=O JDDOJSNHPGULAY-IPZCTEOASA-M 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical class C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000005612 glucoheptonate group Chemical group 0.000 description 1
- 229910000856 hastalloy Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- MYGAJZBZLONIBZ-UHFFFAOYSA-N methyl 2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Cl MYGAJZBZLONIBZ-UHFFFAOYSA-N 0.000 description 1
- 150000005451 methyl sulfates Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229940121136 tecfidera Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/90—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having more than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本申请提供了新的富马酸单甲酯前药。
Description
技术领域
本发明涉及前药。更具体地,本发明涉及富马酸单甲酯的前药、它们的制备方法、含有这些化合物的药物组合物。
背景技术
富马酸二甲酯(DMF)以其抗炎性能和细胞保护特性而闻名。目前能用于治疗多发性硬化症(MS)和银屑病,并分别以名称泰福德(Tecfidera)和Fumaderm销售。众所周知,在给药时,富马酸二甲酯会很快转化为富马酸单甲酯(MMF),并且其生物作用可能是由于MMF。
然而,现有的治疗涉及非常频繁的给药方案和非常高的剂量,这带来了患者依从性的问题。此外,据记载,在药物吸收方面存在高度的患者间变异性,并且食物大大降低了生物利用度。吸收被认为是发生在小肠中,在口服给药后5-6小时达到峰值水平。70-90%的患者会出现明显的副作用。为了改善药代动力学和患者间变异性,包含富马酸酯的控释药物组合物在现有技术中是已知的。示例性控释制剂可以在WO 2007/042034、US 2012/0034274和US 2012/0034303中找到。
现有技术中可用的另一种方法是获得富马酸的不同衍生物,包括单烷基酯和二烷基酯(WO 2002/055066和US 6,355,676)。WO 2002/055063、US 2006/0205659和US 7,157,423公开了某些氨基酸和/或蛋白质-富马酸盐缀合物。WO 2003/087174公开了碳环和氧杂碳环化合物,WO 2006/122652公开了硫代琥珀酸酯。US 20140275048和US 20160228376也公开了富马酸的某些衍生物。
然而,药代动力学不佳的问题仍未得到解决。因此,需要一种新方案以降低给药频率、减少副作用和/或改善现有技术中报道的物理化学性质。
发明内容
本发明提供式(I)的富马酸单甲酯及其药学上可接受的盐的前药。
其中R1和R2独立地为H,或C1-C6直链烷基;R3是C1-C6直链烷基;以及
X-是抗衡离子。
本发明还公开了本发明化合物的合成方法、包含本发明化合物的药物组合物以及本发明化合物的用途。如本文所述的富马酸单甲酯前药的实施方案具有改进的药代动力学参数。
附图说明
图1描述了与直接施用MMF相比,本发明的化合物102在递送富马酸单甲酯(MMF)时具有增强的药代动力学。
具体实施方式
除非另外定义,否则本文使用的所有技术和科学术语具有与本领域的普通技术人员通常理解的含义相同的含义。在一个实施方案中,本文提供式(I)的富马酸单甲酯及其药学上可接受的盐的前药。
其中,
R1和R2独立地为H,或C1-C6直链烷基;R3是C1-C6直链烷基;以及
X-是抗衡离子。
本发明化合物的抗衡离子可以通过选择能够在所述pH范围内电离的药物的解离常数来选择。通过估计任何化合物的离子化和非离子化药物浓度(使用完善的方程,如亨德森-哈塞尔巴尔赫方程(Henderson-Hasselbach equation)),可以改善药物的溶解度和由此获得的吸收性。优选地,所述抗衡离子是药学上可接受的抗衡离子。合适的抗衡离子包括但不限于乙酸盐、苯甲酸盐、苄酸盐、酒石酸氢盐、溴酸盐、碳酸盐、氯化物、柠檬酸盐、依地酸盐、乙二磺酸盐、乙醇酸盐、富马酸盐、葡庚糖酸盐、葡糖酸盐、氢溴酸盐、氢氯化物、碘化物、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基硫酸盐、粘酸盐、萘磺酸盐、硝酸盐、帕莫酸盐(双羟萘酸盐)、磷酸盐和二磷酸盐、水杨酸盐和二水杨酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、甲苯磺酸盐、三乙基碘化物(triethiodide)、戊酸盐等。
表A中提供了一些示例性的本发明式(I)化合物:
表A
本发明的化合物是:
(i)(E)-3-氨基甲酰基-1-(((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物;
(ii)(E)-1-(((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)-3-(甲基氨基甲酰基)吡啶-1-鎓碘化物;
(iii)(E)-3-(二甲基氨基甲酰基)-1-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物;
(iv)(E)-3-(乙基(甲基)氨基甲酰基)-1-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物;
(v)(E)-3-(二乙基氨基甲酰基)-1-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物
(vi)((烟酰氧基)甲基)富马酸甲酯
(vii)(E)-3-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲氧基)羰基)-1-甲基吡啶-1-鎓碘化物
本发明化合物合成的一般示意图
总的来说,本发明的化合物可通过酸A的酯化来生成包含离去基团X(例如氯或溴)的甲酯B而获得。A到B的转化可以在碱(如碳酸氢钠)和合适的试剂(如氯甲基氯磺酸酯(chloromethylchlorosulfate))存在下在溶剂中进行。该反应可以在环境温度下进行,或者在冷却或加热下进行,以促进A向B的转化。卤代甲酯可以与含氮杂环或合适的叔胺(C)反应以生成季盐(D)。含氮杂环的示例可以是烟酰胺或烟酰胺类似化合物、取代的烟酰胺、烟酸脂(nicotinate)或取代的烟酸脂,以获得本发明的化合物。叔胺的R'、R”和R”'可以分别是烷基和/或芳基。酯化过程和季铵化过程可以根据酯化和季铵化的需要和本领域公知情况使用各种条件、试剂、催化剂和溶剂。X-表示如上所述的抗衡离子。
在另一个实施方案中,提供了包含治疗有效量的式(I)化合物的组合物。所述化合物(例如,式(I)化合物)和/或其类似物可以口服、肠胃外(静脉内(IV)、肌肉内(IM)、depo-IM、皮下(SC)和depo-SC)、舌下、鼻内(吸入)、鞘内、透皮(例如,通过透皮贴剂)、局部、离子电渗或直肠给药。通常选择剂型以促进向肌肉或肝脏递送。本领域技术人员已知的剂型适合于递送所述化合物。
在又一个实施方案中,本发明的化合物实现的不仅仅是改善药代动力学和理化性质。使用本发明化合物的优点在于,与未修饰的药物相比,总体上能够实现使用更少的药物/生物活性化合物。这提供了若干益处,包括潜在减少甚至消除不需要的副作用以及减少向需要药物的受试者施用活性分子的剂量和时间。
实施例:
本发明的一些实施例在此仅以示例的方式参考附图进行描述。下面具体详细地参考附图,重点在于所显示的细节是通过示例的方式并且出于对本发明的实施例的说明性讨论的目的。基于此,结合附图进行描述使本领域技术人员清楚可以如何实践本发明的实施例。
实施例1:本发明化合物的合成
本发明列举的化合物按照方案1合成。
富马酸单甲酯(DMT):
方案1:
方案1.富马酸单甲酯衍生物的合成
氯甲基富马酸甲酯(chloromethyl methyl fumarate)(3)的合成:将富马酸单甲酯(5.0g,38.43mmol)溶解在DCM(150mL)中。向溶液中加入氯甲基氯磺酸酯(6.34g,3.96mL,38.43mmol),加入硫酸四丁基铵溶液(2.23g,2.21mL,3.84mmol),并将反应混合物搅拌15分钟。将碳酸氢钠(15.21g,153.72mmol)溶解在水(150mL)中。将碳酸氢钠水溶液滴加到反应混合物中并在室温下搅拌15小时。
后处理(Work up):反应完成后,反应混合物用DCM(100mL)稀释。分离有机层并用DM水(150mL)洗涤以除去过量的碳酸氢钠。有机层进一步用硫酸钠干燥并浓缩以得到粗产物。
纯化:粗化合物通过100-200目硅胶柱色谱纯化,使用8%EtOAc/己烷作为洗脱剂,得到化合物3(3.95g,58%产率)。所得液态化合物在冰箱中保存后固化为白色固体。
氯甲基富马酸甲酯(化合物3):白色固体,1H NMR(300MHz,CDCl3);6.97(d,J=15.9Hz,1H),6.85(d,J=15.9Hz,1H),5.81(s,2H),3.83(s,3H);13C NMR(75MHz,CDCl3);164.9,162.9,135.4,131.8,69.1,52.5。
(E)-1-(((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)-3-(甲基氨基甲酰基)吡啶-1-鎓碘化物衍生物(4b)的合成:
将氯甲基富马酸单甲酯(Chloromethyl monomethyl fumarate)3(2.0g,1.12mmol)、碘化钠(2.52g,1.68mmol)和N-甲基烟酰胺(0.91g,0.674mmol)加入ACN(50mL)中并将反应混合物在90℃下搅拌72小时。
纯化:反应完成后,将反应混合物过滤并用乙腈洗涤。真空浓缩滤液,得到半固体粗产物。将半固体粗产物用溶剂(DCM:乙醚9.5:0.5)超声处理以破碎半固体块。从混合物中倾析出棕色溶剂,得到淡黄色固体产物。重复超声处理和倾析棕色溶剂的过程,直到不存在带颜色杂质。此外,黄色固体用乙醚洗涤,得到目标产物0.950g。
(E)-1-(((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)-3-(甲基氨基甲酰基)吡啶-1-鎓碘化物(化合物4b-SPR11575):黄色固体,51%;1H NMR(300MHz,CDCl3);9.60(s,1H),9.35(d,J=5.1Hz,1H),9.17(s,1H,可与D2O交换),9.04(d,J=8.10Hz,1H),8.38-8.33(m,1H),6.97-6.91(m,1H),6.84-6.78(m,1H),6.61(d,J=2.40Hz,2H),3.75(d,,J=2.4Hz,3H),2.88-2.86(m,3H),13C NMR(75MHz,CDCl3);164.5,163.0,161.3,146.8,145.3,145.1,134.9,133.7,131.5,127.8,79.9,52.5,26.4.ESI-MS(C13H15N2O5 +.I-),观察到(C13H15N2O5+)279.00.
HPLC纯度:98.58%
通过适当改变起始材料并使用相同的反应条件制备化合物4a和4c。
(E)-3-氨基甲酰基-1-(((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物(化合物4a-SPR11574):黄色固体,76%;1H NMR(300MHz,CDCl3);9.62(s,1H),9.36(d,J=6.30Hz,1H),9.06(d,J=8.10Hz,1H),8.61(s,1H,可与D2O交换),8.38-8.34(m,1H),8.23(s,1H,可与D2O交换),6.94(d,J=15.60Hz,1H),6.81(d,J=15.90Hz,1H),6.90(S,2H),3.75(s,3H);13C NMR(75MHz,CDCl3);164.5,162.9,162.5,146.9,145.7,145.5,134.8,133.6,131.5,127.8,79.9,52.5.ESI-MS(C12H13N2O5 +.I-),观察到(C12H13N2O5+)265.02.
HPLC纯度:98.00%
(E)-3-(二甲基氨基甲酰基)-1-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲基)吡啶-1-鎓碘化物(化合物4c-SPR11576):黄色固体47%;1H NMR(300MHz,CDCl3);9.47(s,1H),9.33(d,J=4.5Hz,1H),8.83(d,J=7.20Hz,1H),8.33(d,J=6.30Hz,1H),6.95(d,J=15.60Hz,1H),6.81(d,J=15.90Hz,1H),6.58(s,2H),3.75(s,3H),3.05(s,3H),2.97(s,3H);13C NMR(75MHz,CDCl3);164.5,163.6,162.9,146.0,145.8,143.9,135.8,134.8,131.5,128.1,79.7,52.5,35.1.ESI-MS(C14H17N2O5+.I-),观察到(C14H17N2O5 +)293.10.
HPLC纯度:96.71%
实施例2化合物SPR11577和SPR11578根据方案2合成:
方案2.富马酸单甲酯衍生物的合成
烟酸氯甲酯(6)的合成将烟酸(1.0g,8.13mmol)溶于DCM(50mL)中。向溶液中加入氯甲基氯磺酸酯(0.789g,8.13mmol),加入硫酸四丁基铵溶液(0.472g,0.47mL,0.813mmol),并将两相反应混合物搅拌15分钟。将碳酸氢钠(3.21g,40.65mmol)溶解在水(70mL)中。将碳酸氢钠水溶液滴加到反应混合物中并将反应混合物在室温下搅拌6小时。
后处理(Work up):反应完成后,在DCM中萃取有机层。萃取液用DM水洗涤以除去多余的碳酸氢钠残留物。进一步的有机层用硫酸钠干燥得到粗产物。
纯化:粗化合物通过柱色谱法纯化,使用10%EtOAc/己烷作为洗脱剂,得到560mg,41%。
烟酸氯甲酯(6)1H NMR(300MHz,CDCl3);9.06(s,1H),8.66-8.64(m,1H),8.16-8.13(m,1H),7.30-7.25(m,1H),5.83(s,2H)
((烟醇氧基(nicotinoloxy)甲基)富马酸甲酯(化合物7-SPR11577)的合成:将化合物6(0.657g,3.84mmol)、富马酸单甲酯(0.5g,3.84mmol)和三乙胺(0.46g,0.65mL,4.66mmol)加入DMF(5mL)中并将反应混合物在70℃下搅拌15小时。
后处理(Work up):反应完成后,在DCM中萃取有机层。萃取液用DM水洗涤以除去三乙胺。进一步的有机层用硫酸钠干燥,得到粗产物。
纯化:粗化合物通过柱色谱法纯化,使用25%EtOAc/己烷作为洗脱剂,得到550mg;55%。
((烟醇氧基(nicotinoloxy)甲基)富马酸甲酯(化合物7-SPR11577):黄色固体,1HNMR(300MHz,CDCl3);9.26(d,J=1.2Hz,1H),8.84-8.82(m,1H),8.36-8.32(m,1H),7.46-7.42(m,1H),6.97(d,J=15.90Hz,1H),6.88(d,J=15.90Hz,1H),6.13(s,2H),3.82(s,3H);13C NMR(75MHz,CDCl3);164.9,163.8,163.4,151.2,137.6,135.3,132.1,124.8,123.5,80.1,52.5.ESI-MS(C12H11NO6),观察到(M+1)266.10.
HPLC纯度:99.00%
(E)-3-((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲氧基)羰基)-1-甲基吡啶-1-鎓碘化物(化合物8-SPR11578)的合成将化合物7(0.55g,2.0mmol)和甲基碘(0.58g,0.25mL,4.1mmol)溶于乙腈(10ml)并在室温下搅拌20小时。真空浓缩反应混合物,得到粗化合物。粗化合物用乙醚和DCM(比例为9.5:0.5)洗涤,得到黄色半固体化合物560mg,66%。
(E)-3-(((((4-甲氧基-4-氧代丁-2-烯酰基)氧基)甲氧基)羰基)-1-甲基吡啶-1-鎓碘化物(化合物8-SPR11578):黄色固体,1H NMR(300MHz,CDCl3);9.57-9.43(m,2H),8.96(d,J=8.10Hz,1H),8.38-8.33(m,1H),6.97-6.78(m,2H),6.16(m,2H),4.71(s,3H),3.81(s,3H);13C NMR(75MHz,CDCl3);164.9,163.3,160.2,149.9,146.9,145.3,135.7,131.8,129.1,128.9,80.9,52.6,50.2.ESI-MS(C13H14NO6 +I-),观察到(C13H14NO6 +)280.20。
HPLC纯度:99.14%
实施例3本发明化合物的药代动力学评价:
将本发明的示例性化合物在SD大鼠中进行口服(PO)药代动力学(PK)研究,并将数据与母药MMF进行比较。通过PO途径给6只过夜禁食雄性SD大鼠施用10mpk剂量的MMF和10mpk MMF当量的所需剂量水平的测试化合物。使用的给药载体是MQ水。通过眼窝途径在不同时间点采血。血浆样品储存在-80℃下,以备LC-MS分析。在最后一次采血后处死动物。按照下面给出的体内方案进行给药和采血。使用LC-MS(ABI3200)进行PK分析。使用PRISM软件进行数据分析以确定PK参数,例如Cmax(药物给药后和第二次给药前药物在身体特定腔室或测试区域中达到的最大(或峰值)血清浓度)、Tmax(观察到Cmax的时间)、AUC(血浆药物浓度vs.时间曲线的定积分)、MRT(平均停留时间)和t1/2(当去除率接近指数时,生物系统中特定物质总量的一半被生物过程降解所需的时间)。
所有结果列于表1中。
表1:本发明化合物的药代动力学数据
参数 | MMF | SPR11574 | SPR11575 | SPR11576 | SPR11577 | SPR11578 |
Cmax(nM) | 53976.5 | 28802.02 | 43559.5 | 32348.7 | 64775.73 | 20291.3 |
Tmax(h) | 0.16 | 0.23 | 0.33 | 0.23 | 0.16 | 0.30 |
AUC(nM.h) | 24435.0 | 16482 | 54522.4 | 17825.8 | 31792.5 | 13482.0 |
T1/2(h) | 1.60 | 1.86 | 5.89 | 4.41 | 1.44 | 0.53 |
发现这些化合物在大鼠中有血浆暴露。与母体药物MMF相比,发现化合物102(SPR11575)在大鼠血浆中具有更好的提高的AUC和T1/2。动物对本发明的化合物耐受良好。
图1示出了以直接施用MMF本身和施用化合物102时血液中MMF的量测量的药代动力学参数。从图中可以清楚地看出,与直接施用的MRT相比,化合物102以改善的MRT释放MMF。
·大鼠血浆转化:11574、11575、11576、11577在大鼠血浆中立即转化(离体)。578体外和体内均不完全转化。
·溶解度:溶解度可与富马酸单甲酯相媲美,后者本身极易溶于水。
实施例4前药的稳定性
表2
化合物溶解在乙腈中用于分析
RT:室温/25℃
RF:冷藏/4℃
上面的表2表明分子在RT和RF条件下具有合理的稳定性,最长可达15天。
Claims (7)
1.一种根据下式的化合物:
,
并且,任选地,其中抗衡离子碘被乙酸盐、苯甲酸盐、酒石酸氢盐、溴酸盐、氯化物、柠檬酸盐、乙醇酸盐、富马酸盐、葡庚糖酸盐、葡糖酸盐、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基硫酸盐、粘酸盐、硝酸盐、磷酸盐、二磷酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、甲苯磺酸盐或戊酸盐取代。
2.根据权利要求1所述的化合物,其中所述化合物是
,
并且,任选地,其中抗衡离子碘被乙酸盐、苯甲酸盐、酒石酸氢盐、溴酸盐、氯化物、柠檬酸盐、乙醇酸盐、富马酸盐、葡庚糖酸盐、葡糖酸盐、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基硫酸盐、粘酸盐、硝酸盐、磷酸盐、二磷酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、甲苯磺酸盐或戊酸盐取代。
3.根据权利要求1所述的化合物,其中所述化合物是
,
并且,任选地,其中抗衡离子碘被乙酸盐、苯甲酸盐、酒石酸氢盐、溴酸盐、氯化物、柠檬酸盐、乙醇酸盐、富马酸盐、葡庚糖酸盐、葡糖酸盐、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基硫酸盐、粘酸盐、硝酸盐、磷酸盐、二磷酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、甲苯磺酸盐或戊酸盐取代。
4.根据权利要求1所述的化合物,其中所述化合物是
,
并且,任选地,其中抗衡离子碘被乙酸盐、苯甲酸盐、酒石酸氢盐、溴酸盐、氯化物、柠檬酸盐、乙醇酸盐、富马酸盐、葡庚糖酸盐、葡糖酸盐、乳酸盐、乳糖酸盐、苹果酸盐、马来酸盐、扁桃酸盐、甲磺酸盐、甲基硫酸盐、粘酸盐、硝酸盐、磷酸盐、二磷酸盐、硬脂酸盐、琥珀酸盐、硫酸盐、酒石酸盐、甲苯磺酸盐或戊酸盐取代。
5.一种根据下式的化合物:
。
6.一种根据下式的化合物:
,
并且,任选地,其中抗衡离子碘被不同的抗衡离子取代。
7.制备根据权利要求1所述的化合物的方法,
所述方法包括:
(i)按以下酯化富马酸单甲酯(A),生成甲酯(B):
以及
(ii)按以下使甲酯 (B) 与含氮杂环反应,生成季铵盐 (D) :
其中X是离去基团,是含氮杂环,X-是抗衡离子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962835115P | 2019-04-17 | 2019-04-17 | |
US62/835,115 | 2019-04-17 | ||
PCT/US2020/028302 WO2020214693A1 (en) | 2019-04-17 | 2020-04-15 | Prodrugs of monomethyl fumarate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114286811A CN114286811A (zh) | 2022-04-05 |
CN114286811B true CN114286811B (zh) | 2024-03-08 |
Family
ID=72838395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080041560.5A Active CN114286811B (zh) | 2019-04-17 | 2020-04-15 | 富马酸单甲酯的前药 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11142501B2 (zh) |
EP (1) | EP3956287A4 (zh) |
JP (1) | JP7406566B2 (zh) |
CN (1) | CN114286811B (zh) |
CA (1) | CA3175830A1 (zh) |
WO (1) | WO2020214693A1 (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3360544A (en) * | 1963-07-19 | 1967-12-26 | Monsanto Co | Processes for preparing alkyl hydroxyalkyl fumarates |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
CN1386116A (zh) * | 2000-07-19 | 2002-12-18 | 昭和电工株式会社 | 富马酸酯衍生物和它的制造方法 |
CN101932562A (zh) * | 2007-12-20 | 2010-12-29 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂190的氨基甲酰基化合物 |
CN102123763A (zh) * | 2008-08-19 | 2011-07-13 | 什诺波特有限公司 | 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法 |
CN103607888A (zh) * | 2011-04-08 | 2014-02-26 | 斯法尔制药私人有限公司 | 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法 |
CN105142628A (zh) * | 2012-12-21 | 2015-12-09 | 比奥根玛公司 | 氘取代的富马酸盐衍生物 |
CN105452213A (zh) * | 2013-03-14 | 2016-03-30 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
US9409872B1 (en) * | 2015-02-16 | 2016-08-09 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
CN106946701A (zh) * | 2017-03-28 | 2017-07-14 | 杨立川 | 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用 |
CN107382721A (zh) * | 2017-07-04 | 2017-11-24 | 黄山学院 | Box‑Behnken设计效应面法优化合成富马酸单环己酯的方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727151A (en) * | 1974-06-24 | 1988-02-23 | Interx Research Corporation | Labile quaternary ammonium salts as prodrugs |
US4428935A (en) * | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
JPH01233286A (ja) * | 1988-03-11 | 1989-09-19 | Sumitomo Pharmaceut Co Ltd | 新規セフエム誘導体 |
US6110970A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Nitrogen-containing oxyalkylene esters and uses thereof |
US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
WO2014031892A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
EP2903614B1 (en) * | 2012-10-05 | 2021-09-29 | Sphaera Pharma Pte. Ltd | Novel compounds, their synthesis and their uses |
ES2731837T3 (es) * | 2012-12-21 | 2019-11-19 | Ratiopharm Gmbh | Profármacos de fumarato de monometilo (MMF) |
US8669281B1 (en) * | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
US9302977B2 (en) * | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
US20160214948A1 (en) * | 2013-09-27 | 2016-07-28 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
MA40985A (fr) * | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
WO2017079195A1 (en) * | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
WO2017218580A1 (en) * | 2016-06-14 | 2017-12-21 | Rejuvenation Therapeutics Corporation | Synthetic methods for the preparation of nicotinamide riboside and related compounds |
-
2020
- 2020-04-15 WO PCT/US2020/028302 patent/WO2020214693A1/en unknown
- 2020-04-15 JP JP2021562129A patent/JP7406566B2/ja active Active
- 2020-04-15 CN CN202080041560.5A patent/CN114286811B/zh active Active
- 2020-04-15 EP EP20792230.3A patent/EP3956287A4/en active Pending
- 2020-04-15 CA CA3175830A patent/CA3175830A1/en active Pending
-
2021
- 2021-02-12 US US17/174,450 patent/US11142501B2/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3360544A (en) * | 1963-07-19 | 1967-12-26 | Monsanto Co | Processes for preparing alkyl hydroxyalkyl fumarates |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
CN1386116A (zh) * | 2000-07-19 | 2002-12-18 | 昭和电工株式会社 | 富马酸酯衍生物和它的制造方法 |
CN101932562A (zh) * | 2007-12-20 | 2010-12-29 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂190的氨基甲酰基化合物 |
CN102123763A (zh) * | 2008-08-19 | 2011-07-13 | 什诺波特有限公司 | 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法 |
CN103607888A (zh) * | 2011-04-08 | 2014-02-26 | 斯法尔制药私人有限公司 | 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法 |
CN105142628A (zh) * | 2012-12-21 | 2015-12-09 | 比奥根玛公司 | 氘取代的富马酸盐衍生物 |
CN105452213A (zh) * | 2013-03-14 | 2016-03-30 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
US9409872B1 (en) * | 2015-02-16 | 2016-08-09 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
CN106946701A (zh) * | 2017-03-28 | 2017-07-14 | 杨立川 | 一种水杨酸基富马酸盐衍生物及在治疗帕金森症和其他神经退行性疾病应用 |
CN107382721A (zh) * | 2017-07-04 | 2017-11-24 | 黄山学院 | Box‑Behnken设计效应面法优化合成富马酸单环己酯的方法 |
Non-Patent Citations (2)
Title |
---|
富马酸单甲酯-3-没食子酸异戊酯的合成与性能研究;袁加程;刘长春;;食品研究与开发(07);70-73 * |
胡春.有机化学(第二版).中国医药科技出版社,2013,第205页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114286811A (zh) | 2022-04-05 |
JP7406566B2 (ja) | 2023-12-27 |
JP2022537872A (ja) | 2022-08-31 |
CA3175830A1 (en) | 2020-10-22 |
US20210163414A1 (en) | 2021-06-03 |
EP3956287A4 (en) | 2022-12-14 |
US11142501B2 (en) | 2021-10-12 |
WO2020214693A1 (en) | 2020-10-22 |
EP3956287A1 (en) | 2022-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI766842B (zh) | 抗真菌化合物及其製備方法 | |
US11198683B2 (en) | Method for preparing tyrosine kinase inhibitor and derivative thereof | |
JP2015536940A (ja) | 抗ウイルス性ホスホネート類似体及びその製造方法 | |
JP6374436B2 (ja) | 純粋なエルロチニブ | |
US20160355533A1 (en) | Crystalline Fosaprepitant Dicyclohexylamine Salt And Its Preparation | |
CN110891947A (zh) | 制备艾乐替尼或其药学上可接受的盐的方法 | |
WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
CN114286811B (zh) | 富马酸单甲酯的前药 | |
TW202210461A (zh) | 一種(s)—2—胺基—3—(4—(2,3—二甲基吡啶—4—基)苯基)丙酸甲酯二酸鹽的製備方法 | |
CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
TWI548615B (zh) | 化合物、及其製造方法 | |
US6677456B2 (en) | Pentacyclic taxan compound | |
US11760751B2 (en) | Benzo 2-azaspiro[4.4]nonane compound and use thereof | |
EP4245750A1 (en) | Amino-combretastatin derivative and use thereof | |
CN109651377B (zh) | 一种治疗癌症的化合物及其用途 | |
JP2021514353A (ja) | ベンゾジアゼピン誘導体塩酸塩および結晶形、その製造方法および用途 | |
CN103819461B (zh) | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 | |
CN116874484A (zh) | Gper激动剂及应用 | |
EP3808752A1 (en) | Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof | |
JP2807537B2 (ja) | インドール誘導体およびそれらを有効成分とする抗癌剤 | |
EP4089095A1 (en) | Deuterated thienopyridine compound | |
CN117105948A (zh) | 一类二氘代喜树碱衍生物及制备方法 | |
CN117327094A (zh) | 化合物或其药学上可接受的盐及其晶型 | |
CN116867789A (zh) | 一种伊喜替康衍生物的制备方法及其中间体 | |
CN115710257A (zh) | 一种酰胺化合物的硫酸盐晶型、药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |